EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study

Raphatphorn Navakanitworakul iD, Pirun Saelue, Tipparat Penglong, Piyatida Molika, Natakorn Nokchan iD, Natta Tansila, Hansuk Buncherd, Supinya Thanapongpichat, Kanitta Srinoun iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0331479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Raphatphorn Navakanitworakul und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Exosomes, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science, Research, and Innovation Fund (NSRF) and Prince of Songkla University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a hematologic malignancy originating from hematopoietic stem cells and driven by the BCR-ABL fusion oncogene. Imatinib (IM), a tyrosine kinase inhibitor, is commonly used as a frontline therapy for CML. However, some patients exhibit primary resistance or show persistent molecular evidence of disease despite treatment. Emerging studies indicate that exosome-derived microRNAs (miRNAs) play a role in mediating drug resistance and may serve as promising biomarkers for cancer diagnosis and predicting therapeutic response. This study aimed to investigate the plasma exosomal miRNA expression profiles in CML patients to identify potential biomarkers associated with IM resistance. Exosomes were isolated from plasma samples of both IM-sensitive and IM-resistant CML patients. The exosomal miRNA content was analyzed using RNA sequencing, followed by differential expression analysis, which revealed 13 upregulated and 21 downregulated miRNAs in IM-resistant patients. Subsequent bioinformatics analysis indicated significant enrichment in pathways related to autophagy and PI3K-Akt signaling. Notably, miR-451a and miR-16–2-3p were among the most significantly upregulated miRNAs in exosomes from IM-resistant individuals. Interestingly, miR-16–2-3p expression showed a strong inverse correlation with clinical laboratory results, specifically blood urea nitrogen and creatinine levels. This pilot study identified plasma exosomal miRNAs, particularly miR-451a and miR-16–2-3p, as potential biomarkers for imatinib resistance in chronic myeloid leukemia. Target gene prediction was performed to explore their regulatory roles. Despite the limited sample size, these findings enhance our understanding of drug resistance mechanisms and warrant further validation in larger cohorts to assess their clinical relevance and therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveExosomesDrug Resistance, NeoplasmMicroRNAsHumansPilot ProjectsMaleFemaleMiddle AgedAdultGene Expression ProfilingAgedAntineoplastic AgentsBiomarkers, Tumor

Substanzen

Imatinib MesylateMicroRNAsAntineoplastic AgentsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Hematology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand.
  • Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
  • Translational Medicine Research Center, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Faculty of Medical Technology, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

ORCID-Profile: Raphatphorn Navakanitworakul, Natakorn Nokchan, Kanitta Srinoun

Förderung

  • National Science, Research, and Innovation Fund (NSRF) and Prince of Songkla University

Zitieren

APA

Navakanitworakul, R., Saelue, P., Penglong, T., Molika, P., Nokchan, N., Tansila, N., Buncherd, H., Thanapongpichat, S., & Srinoun, K. (2025). Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study. PLOS One. https://doi.org/10.1371/journal.pone.0331479

Vancouver

Navakanitworakul R, Saelue P, Penglong T, Molika P, Nokchan N, Tansila N, et al. Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study. PLOS One. 2025. doi:10.1371/journal.pone.0331479

BibTeX
@article{Navakanitworakul2025,
  author = {Navakanitworakul, Raphatphorn and Saelue, Pirun and Penglong, Tipparat and Molika, Piyatida and Nokchan, Natakorn and Tansila, Natta and Buncherd, Hansuk and Thanapongpichat, Supinya and Srinoun, Kanitta},
  title = {Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0331479}
}
Kostenlos starten →